Analyst Price Target is $9.50
▲ +61.02% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aytu Biopharma in the last 3 months. The average price target is $9.50, with a high forecast of $14.50 and a low forecast of $3.00. The average price target represents a 61.02% upside from the last price of $5.90.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Aytu Biopharma. This Buy consensus rating has held steady for over two years.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.